Foghorn Therapeutics, Inc. (FHTX)
6.01
-0.21
(-3.38%)
USD |
NASDAQ |
Aug 28, 13:01
Foghorn Therapeutics Debt to Equity Ratio : -0.5319 for June 30, 2026
Debt to Equity Ratio Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Debt to Equity Ratio Data
| Date | Value |
|---|---|
| June 30, 2026 | -0.5319 |
| March 31, 2026 | -0.5496 |
| December 31, 2025 | -0.3804 |
| September 30, 2025 | -0.2513 |
| June 30, 2025 | -0.3091 |
| March 31, 2025 | -0.5653 |
| December 31, 2024 | -0.8156 |
| September 30, 2024 | -1.381 |
| June 30, 2024 | -2.857 |
| March 31, 2024 | -0.4409 |
| December 31, 2023 | -0.5839 |
| September 30, 2023 | -0.8204 |
| Date | Value |
|---|---|
| June 30, 2023 | -0.9715 |
| March 31, 2023 | -2.027 |
| December 31, 2022 | 459.88 |
| September 30, 2022 | 2.186 |
| June 30, 2022 | 1.151 |
| March 31, 2022 | 0.7815 |
| December 31, 2021 | 0.6022 |
| September 30, 2021 | 0.9869 |
| June 30, 2021 | 0.7848 |
| March 31, 2021 | 0.6583 |
| December 31, 2020 | 0.5609 |
| September 30, 2020 | -1.855 |
Debt to Equity Ratio Definition
The debt to equity ratio measures the (Long Term Debt + Current Portion of Long Term Debt) / Total Shareholders' Equity. This metric is useful when analyzing the health of a company's balance sheet.
Debt to Equity Ratio Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Debt to Equity Ratio Benchmarks
| Prime Medicine, Inc. | 2.825 |
| Arrowhead Pharmaceuticals, Inc. | 2.956 |
| Oncolytics Biotech, Inc. | -0.0726 |
| Sangamo Therapeutics, Inc. | -1.020 |
| Sarepta Therapeutics, Inc. | 0.6845 |
Debt to Equity Ratio Related Metrics
| Total Assets (Quarterly) | 203.39M |
| Total Liabilities (Quarterly) | 284.43M |
| Shareholders Equity (Quarterly) | -81.04M |
| Current Ratio | 3.362 |
| Net Debt Paydown Yield | -0.58% |